Page last updated: 2024-08-24

irinotecan and Obesity

irinotecan has been researched along with Obesity in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujita, K; Sasaki, Y	1
Gandhi, A; Ghose, R; Mallick, P; Shah, P	1
Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ	1
Baker, SD; Chatelut, E; Mathijssen, RH; Rowinsky, EK; Sparreboom, A; Verweij, J; Wolff, AC	1

Reviews

1 review(s) available for irinotecan and Obesity

Article	Year
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'. Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:1 Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur	2014

Article

Year

Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.

Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:1

Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur

2014

Trials

1 trial(s) available for irinotecan and Obesity

Article	Year
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome	2011

Article

Year

Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.

European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome

2011

Other Studies

2 other study(ies) available for irinotecan and Obesity

Article	Year
Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life sciences, 2015, Oct-15, Volume: 139 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Feces; Glucuronates; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Necrosis Factor-alpha	2015
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan	2007

Article

Year

Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice.

Life sciences, 2015, Oct-15, Volume: 139

Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Colorectal Neoplasms; Feces; Glucuronates; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Necrosis Factor-alpha

2015

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Body Size; Body Surface Area; Body Weight; Camptothecin; Carboplatin; Cisplatin; Cytosine; Dioxolanes; Docetaxel; Doxorubicin; Humans; Irinotecan; Metabolic Clearance Rate; Obesity; Paclitaxel; Taxoids; Topotecan

2007